HitGen Announces Achievement of Milestone from DEL Discovery Alliance with Merck & Co., Inc., Kenilworth, NJ., USA

“To date we have initiated screening efforts on multiple Merck discovery programs from various therapeutic areas. These programs are at various stages of screening, selection, synthesis and validation and are all progressing. These achievements mark the continued progress and success of the discovery collaboration between the companies spanning a range of discovery programs. We look forward to announcing future milestones as the programs progress,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

About HitGen Inc.

HitGen is a rapidly growing biotech company with headquarters and main research facilities based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug centred around the design, assembly and interrogation of DNA encoded chemical libraries (DELs). HitGen’s DELs contain nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and agrochemical solutions.

For more information, please visit www.hitgen.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005203/en/